Parse

See where your brand stands in AI recommendations.

Products

  • Brands
  • Markets
  • Work with us
  • Pricing

Resources

  • Research
  • Methodology
  • Blog
  • MCP

© 2026 Parse. All rights reserved.

LegalPrivacy PolicyTerms of Service
Parse
Pricing
Sign inCheck your brand
  1. Brands
  2. EarlyDiagnostics
BrandsEarlyDiagnostics

EarlyDiagnostics in AI answers

Follow this brand

Data as of Sep 21, 2026 · Based on 3,332,371 AI responses across 10,526 prompts · See how Parse measures this

Explore

Top cited sources

  • sbir.cancer.gov (opens in a new tab)100%

Questions

EarlyDiagnostics logoEarlyDiagnosticsearlydx.com · Low evidence
Low evidence

EarlyDiagnostics (EarlyDx) is building a platform that converts cell-free DNA into whole-body molecular insights using its proprietary MethylScan epigenomic technology, enabling early disease detection, patient risk stratification, precision medicine, and longitudinal health monitoring from a single blood draw. The company offers CancerRadar, a blood test for highly accurate cancer detection and localization, and EarlyDx-Cloud, a one-stop bioinformatics solution to support liquid biopsy-based diagnostics, therapy selection, and treatment monitoring. Its technologies also include cfSNV for calling mutations from blood and cfTrack for non-invasive monitoring of MRD, recurrence, and evolution across oncology and liver disease.

Parse Score

32

No contexts measured yet.

  • Named in
  • 7% · 2 engines

    Excerpts where EarlyDiagnostics appeared in the AI's answer

    Google AI Mode · excerpt
    EarlyDiagnostics (EarlyDx) – Employs a proprietary epigenomic platform (MethylScan ) utilizing a single blood draw for cell-free DNA analysis.
    ChatGPT Search · excerpt
    EarlyDiagnostics — develops blood-based cancer detection and an AI platform intended to support precision medicine decisions using methylation data.